{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T16:39:46Z","timestamp":1778603986735,"version":"3.51.4"},"reference-count":61,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T00:00:00Z","timestamp":1556236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002426","name":"Telethon Foundation","doi-asserted-by":"publisher","award":["TGTG01 TGTG02"],"award-info":[{"award-number":["TGTG01 TGTG02"]}],"id":[{"id":"10.13039\/501100002426","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.ymthe.2019.04.014","type":"journal-article","created":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T23:55:51Z","timestamp":1555718151000},"page":"1215-1227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease"],"prefix":"10.1016","volume":"27","author":[{"given":"Giorgia","family":"Squeri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Passerini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cecilia","family":"Laudisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Tomasoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Deodato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Alice","family":"Donati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Aiuti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Ester","family":"Bernardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Gentner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Naldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Annoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Biffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2019.04.014_bib1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nature15818","article-title":"Gene therapy returns to centre stage","volume":"526","author":"Naldini","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2019.04.014_bib2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/gt.2009.148","article-title":"Progress and prospects: immune responses to viral vectors","volume":"17","author":"Nayak","year":"2010","journal-title":"Gene Ther."},{"issue":"4A","key":"10.1016\/j.ymthe.2019.04.014_bib3","first-page":"2345","article-title":"Inhibitory effects of human sera on adenovirus-mediated gene transfer into rat liver","volume":"18","author":"Kuriyama","year":"1998","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ymthe.2019.04.014_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.04.014_bib5","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/gt.2008.54","article-title":"Immunity to adeno-associated virus vectors in animals and humans: a continued challenge","volume":"15","author":"Zaiss","year":"2008","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2019.04.014_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.014_bib7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nrg2971","article-title":"State-of-the-art gene-based therapies: the road ahead","volume":"12","author":"Kay","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.ymthe.2019.04.014_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2019.04.014_bib9","doi-asserted-by":"crossref","first-page":"1233151","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2019.04.014_bib10","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2019.04.014_bib11","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2019.04.014_bib12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.trsl.2012.12.018","article-title":"Immune responses in liver-directed lentiviral gene therapy","volume":"161","author":"Annoni","year":"2013","journal-title":"Transl. Res."},{"key":"10.1016\/j.ymthe.2019.04.014_bib13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/humu.1380060403","article-title":"Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications","volume":"6","author":"Scott","year":"1995","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ymthe.2019.04.014_bib14","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","article-title":"Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study","volume":"125","author":"Aldenhoven","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.014_bib15","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1182\/blood-2010-04-278234","article-title":"Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model","volume":"116","author":"Visigalli","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.014_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.bmt.1705934","article-title":"Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome","volume":"41","author":"Tolar","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.ymthe.2019.04.014_bib17","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ymgme.2016.01.011","article-title":"Enzyme replacement therapy prior to haematopoietic stem cell transplantation in Mucopolysaccharidosis Type I: 10 year combined experience of 2 centres","volume":"117","author":"Ghosh","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.04.014_bib18","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/S0140-6736(03)13311-9","article-title":"Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I","volume":"361","author":"Kakavanos","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2019.04.014_bib19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.molmed.2003.08.004","article-title":"Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder","volume":"9","author":"Brooks","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymthe.2019.04.014_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.addr.2017.05.004","article-title":"Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives","volume":"118","author":"Solomon","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2019.04.014_bib21","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ymgme.2015.11.001","article-title":"Immune response to enzyme replacement therapies in lysosomal storage diseases and the role of immune tolerance induction","volume":"117","author":"Kishnani","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.04.014_bib22","doi-asserted-by":"crossref","first-page":"e67052","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2019.04.014_bib23","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.04.014_bib24","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.omtm.2017.09.008","article-title":"A Humoral Immune Response Alters the Distribution of Enzyme Replacement Therapy in Murine Mucopolysaccharidosis Type I","volume":"8","author":"Le","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2019.04.014_bib25","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ymgme.2013.03.005","article-title":"Enzyme replacement therapy started at birth improves outcome in difficult-to-treat organs in mucopolysaccharidosis I mice","volume":"109","author":"Baldo","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.04.014_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0169-409X(98)00009-X","article-title":"Adjuvant activity of incomplete Freund\u2019s adjuvant","volume":"32","author":"Jensen","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ymthe.2019.04.014_bib27","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/j.1538-7836.2012.04791.x","article-title":"Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity","volume":"10","author":"Kuether","year":"2012","journal-title":"J.\u00a0Thromb. Haemost."},{"key":"10.1016\/j.ymthe.2019.04.014_bib28","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1182\/blood-2006-11-059873","article-title":"The immune response to lentiviral-delivered transgene is modulated in\u00a0vivo by transgene-expressing antigen-presenting cells but not by CD4+CD25+ regulatory T\u00a0cells","volume":"110","author":"Annoni","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2019.04.014_bib29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ymthe.2006.03.015","article-title":"Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig","volume":"14","author":"Ponder","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.014_bib30","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/sj.mt.6300112","article-title":"Improvements in mucopolysaccharidosis I mice after adult retroviral vector-mediated gene therapy with immunomodulation","volume":"15","author":"Ma","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.014_bib31","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.4049\/jimmunol.169.7.3760","article-title":"Differential sensitivity of naive and memory CD8+ T\u00a0cells to apoptosis in\u00a0vivo","volume":"169","author":"Grayson","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2019.04.014_bib32","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.4049\/jimmunol.1101141","article-title":"Selective resistance of CD44hi T\u00a0cells to p53-dependent cell death results in persistence of immunologic memory after total body irradiation","volume":"187","author":"Yao","year":"2011","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2019.04.014_bib33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3389\/fimmu.2014.00140","article-title":"Antigen cross-presentation of immune complexes","volume":"5","author":"Platzer","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2019.04.014_bib34","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ymgme.2016.02.006","article-title":"Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies","volume":"117","author":"Xue","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.04.014_bib35","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tips.2009.11.001","article-title":"Immunological mechanism underlying the immune response to recombinant human protein therapeutics","volume":"31","author":"Sauerborn","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ymthe.2019.04.014_bib36","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clim.2013.09.006","article-title":"T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation","volume":"149","author":"Jawa","year":"2013","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ymthe.2019.04.014_bib37","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mus.22136","article-title":"Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease","volume":"44","author":"Banati","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymthe.2019.04.014_bib38","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2019.04.014_bib39","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/00007890-199211000-00015","article-title":"Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody","volume":"54","author":"Anasetti","year":"1992","journal-title":"Transplantation"},{"key":"10.1016\/j.ymthe.2019.04.014_bib40","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.bbmt.2005.03.002","article-title":"A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease","volume":"11","author":"Carpenter","year":"2005","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2019.04.014_bib41","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/j.1875-9114.1998.tb03929.x","article-title":"Monoclonal antibodies in the treatment of steroid-resistant acute graft-versus-host disease","volume":"18","author":"Tse","year":"1998","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ymthe.2019.04.014_bib42","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/mt.2012.133","article-title":"Administration of Anti-CD3 Antibodies Modulates the Immune Response to an Infusion of \u03b1-glucosidase in Mice","volume":"20","author":"Ohashi","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2019.04.014_bib43","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/01.tp.0000183289.79693.3d","article-title":"An irradiation-free nonmyeloablative bone marrow transplantation model: importance of the balance between donor T-cell number and the intensity of conditioning","volume":"80","author":"Kuwatani","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.ymthe.2019.04.014_bib44","doi-asserted-by":"crossref","first-page":"3071214","DOI":"10.1155\/2016\/3071214","article-title":"Conditioning with Fludarabine-Busulfan versus Busulfan-Cyclophosphamide Is Associated with Lower aGVHD and Higher Survival but More Extensive and Long Standing Bone Marrow Damage","volume":"2016","author":"He","year":"2016","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.ymthe.2019.04.014_bib45","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2013.11.027","article-title":"Fludarabine and exposure-targeted busulfan compares favorably with busulfan\/cyclophosphamide-based regimens in pediatric hematopoietic cell transplantation: maintaining efficacy with less toxicity","volume":"20","author":"Bartelink","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2019.04.014_bib46","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.bbmt.2015.02.011","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines","volume":"21","author":"Aldenhoven","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymthe.2019.04.014_bib47","first-page":"161","article-title":"Specific inhibition of antibody production. I. Protein-over loading paralysis","volume":"5","author":"Dresser","year":"1962","journal-title":"Immunology"},{"key":"10.1016\/j.ymthe.2019.04.014_bib48","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2019.04.014_bib49","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-3083.2007.01909.x","article-title":"The cross-priming pathway: a portrait of an intricate immune system","volume":"65","author":"Basta","year":"2007","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.ymthe.2019.04.014_bib50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00281-004-0174-2","article-title":"Induction of antigen cross-presentation by Toll-like receptors","volume":"26","author":"Datta","year":"2005","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.ymthe.2019.04.014_bib51","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00281-004-0173-3","article-title":"Natural endogenous adjuvants","volume":"26","author":"Rock","year":"2005","journal-title":"Springer Semin. Immunopathol."},{"key":"10.1016\/j.ymthe.2019.04.014_bib52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1600-065X.1997.tb00969.x","article-title":"Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity","volume":"156","author":"Zinkernagel","year":"1997","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2019.04.014_bib53","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1002\/jps.21765","article-title":"Effect of route of administration of human recombinant factor VIII on its immunogenicity in Hemophilia A mice","volume":"98","author":"Peng","year":"2009","journal-title":"J.\u00a0Pharm. Sci."},{"key":"10.1016\/j.ymthe.2019.04.014_bib54","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1084\/jem.20111171","article-title":"Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans","volume":"208","author":"Caskey","year":"2011","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2019.04.014_bib55","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1542\/peds.2007-3847","article-title":"Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I","volume":"123","author":"Clarke","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2019.04.014_bib56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years","volume":"90","author":"Sifuentes","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.04.014_bib57","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J.\u00a0Pediatr."},{"key":"10.1016\/j.ymthe.2019.04.014_bib58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ymgme.2008.10.009","article-title":"A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I","volume":"96","author":"Giugliani","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2019.04.014_bib59","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1073\/pnas.252784899","article-title":"Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB","volume":"100","author":"Ohmi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2019.04.014_bib60","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nbt1049","article-title":"Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters","volume":"23","author":"Amendola","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2019.04.014_bib61","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S1096-7192(03)00116-1","article-title":"Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow","volume":"79","author":"Zheng","year":"2003","journal-title":"Mol. Genet. Metab."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619301807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001619301807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T03:32:59Z","timestamp":1721187179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001619301807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":61,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1525001619301807"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.04.014","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting a Pre-existing Anti-transgene T Cell Response for Effective Gene Therapy of MPS-I in the Mouse Model of the Disease","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2019.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors.","name":"copyright","label":"Copyright"}]}}